Lung Cancer Clinical Trial
Official title:
Longitudinal Measurement of Pain and Other Symptoms of Non-Small Cell Lung Cancer (NSCLC) Patients Following Thoracic Surgery
Primary Objectives:
- To longitudinally assess the natural history of symptoms (prevalence, severity,
patterns of symptoms, and the relationship of physical and psychological distress)
among post-thoracic surgery for non-small cell lung cancer patients with early stage
(stage I-IIIA) disease.
- To determine crisis events (when symptoms are most severe), their relationship with
cancer therapy, surgical techniques and disease, and their relationship with function
and quality of life; and to determine current practice patterns of symptom control
throughout the six months of the post-surgical phase.
- To determine the utility of a weekly, telephone-administered interactive voice response
symptom assessment (IVR-MDASI) for identifying emergent clinically significant symptoms
in this population.
- To develop symptom severity critical values and critical treatment algorithms for
post-operative symptom control for NSCLC patients.
Before surgery, you will be asked to complete four surveys about your mood, symptoms,
quality of life, and smoking history. Completing the questionnaires will take about 20
minutes. You will be asked for some information about age, sex, race, education, marital
status, and employment status (full-time, part-time, unemployed). Before surgery, the
research nurse will teach you how to use the special telephone system, called an Interactive
Voice Response (IVR) telephone system. This system is used for tracking symptoms at home. An
instruction pamphlet will also be given to you.
Three days after surgery, while you are in the hospital, you will be asked by the research
nurse to again complete one questionnaires that measures your symptoms.
Once you are home from the hospital, the automatic telephone IVR system will call at a
prescheduled time that is convenient for you. The phone call will take about four minutes to
complete. The IVR will call once a week for the first 3 months after surgery, and then every
two weeks for an additional 3 months.
The research nurse will call you one week after surgery and then one month, three months,
and six months to complete four questionnaires about symptoms, mood, quality of life, and
smoking history. It will take about 20 minutes to complete the questionnaires.
The information collected by the IVR is for research purposes only, and you must report any
symptoms that you are concerned about to your physicians or nurses.
Should severe symptoms develop, research staff will notify the your treatment team.
This is an investigational study. About 112 patients will participate in this study. All
will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|